Document Detail

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.
MedLine Citation:
PMID:  19995389     Owner:  NLM     Status:  MEDLINE    
An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.
Antonio Maria Risitano; Carmine Selleri; Bianca Serio; Giovanni Fernando Torelli; Alexander Kulagin; Sébastien Maury; Jörg Halter; Vikas Gupta; Andrea Bacigalupo; Gerard Sociè; André Tichelli; Hubert Schrezenmeier; Judith Marsh; Jakob Passweg; Bruno Rotoli;
Related Documents :
6199989 - Effects of intraperitoneal 6% dextran 70 on serum immunoglobulin levels, peripheral cel...
16014149 - Clinical remission following monoclonal anti-cd20 therapy in two children with chronic ...
23295819 - Epidemiology of oestrus ovis (diptera: oestridae) in sheep in botucatu, state of são p...
23439419 - Acute ankle sprain in a mouse model.
9407939 - Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytop...
24561149 - Sex-related differences in outcomes following transcatheter or surgical aortic valve re...
25197109 - Effect of rigid cervical collar on tracheal intubation using airtraq(®).
8417939 - Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy....
23470089 - Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheu...
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article     Date:  2009-12-07
Journal Detail:
Title:  British journal of haematology     Volume:  148     ISSN:  1365-2141     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-05-04     Completed Date:  2010-06-29     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  791-6     Citation Subset:  IM    
Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Italy. <>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anemia, Aplastic / drug therapy*
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / adverse effects,  therapeutic use*
Cyclosporine / therapeutic use
Drug Therapy, Combination
Immunosuppressive Agents / adverse effects,  therapeutic use*
Injections, Subcutaneous
Middle Aged
Pilot Projects
Prospective Studies
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 0/Immunosuppressive Agents; 3A189DH42V/alemtuzumab; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Modelling parasite dissemination: Host cell subversion and immune evasion by Toxoplasma gondii.
Next Document:  (188)Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell...